Mark Mallon

This profile gathers the share dealings of Mark Mallon across 2 companies, led by Ironwood Pharmaceuticals Inc and Neogenomics Inc. The record holds 13 filings, for trades running from 9 January 2019 to 1 March 2022.

Both buying and selling appear: 1 purchase worth €461k, against 5 sales worth €538k. The net balance comes to €77k on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 7 share grants.

The latest filing, published on 3 March 2022, reports a share grant in Neogenomics Inc. The latest purchase dates back some time: it was published 1,799 days ago, on 6 December 2021. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.